Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

GNMK
GenMark Diagnostics, Inc. Common Stock
stock NASDAQ

Inactive
Apr 21, 2021
24.04USD0.000%(0.00)3,825,678
Pre-market
Dec 31, 1969 7:00:00 PM EST
0.00USD-100.000%(-24.04)0
After-hours
Dec 31, 1969 7:00:00 PM EST
0.00USD0.000%(0.00)0
OverviewHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Apr 22, 2021
01:39AM EDT  Roche (RHHBY) said it plans to complete the acquisition of GenMark Diagnostics Inc. (GNMK), later Thursday.   RTTNews
01:28AM EDT  Roche Buys Shares In Tender Offer For GenMark Diagnostics   RTTNews
Mar 26, 2021
07:28AM EDT  The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs   Benzinga
Mar 25, 2021
10:18PM EDT  Swiss drug major Roche (RHHBY) said that it has commenced a cash tender offer for all of the outstanding shares of common stock of GenMark Diagnostics Inc. (GNMK) at a price of $24.05 per share.   RTTNews
Mar 17, 2021
02:02PM EDT  GENMARK INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of GenMark Diagnostics - GNMK   Business Wire
10:40AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2021   Benzinga
07:43AM EDT  The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes   Benzinga
07:34AM EDT  BTIG Downgrades GenMark Diagnostics to Neutral   Benzinga
06:49AM EDT  Cowen & Co. Downgrades GenMark Diagnostics to Market Perform, Raises Price Target to $24.05   Benzinga
Mar 16, 2021
10:37AM EDT  Canaccord Genuity Downgrades GenMark Diagnostics to Hold   Benzinga
08:17AM EDT  The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study   Benzinga
Mar 15, 2021
02:51PM EDT  Mid-Afternoon Market Update: Dow Rises 50 Points; Shaw Communications Shares Spike Higher   Benzinga
12:04PM EDT  Mid-Day Market Update: Intec Pharma Jumps Following Merger News; HighPoint Resources Shares Plunge   Benzinga
11:47AM EDT  Needham Downgrades GenMark Diagnostics to Hold   Benzinga
10:25AM EDT  Mid-Morning Market Update: Markets Edge Higher; Roche To Acquire GenMark Diagnostics In $1.8B Deal   Benzinga
03:48AM EDT  Roche Boosts Diagnostics Portfolio With $1.8B Bet On COVID-19 Test Manufacturer GenMark   Benzinga
02:22AM EDT  Swiss drug major Roche Group (RHHBY) announced Monday its agreement to acquire GenMark Diagnostics (GNMK) for $24.05 per share in an all-cash transaction. The total transaction value would be around $1.8 billion on a fully diluted basis.   RTTNews
02:04AM EDT  Roche Enters Definitive Merger Agreement To Acquire GenMark At $24.05/Shr   RTTNews
Feb 26, 2021
08:17AM EST  The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida   Benzinga
Feb 25, 2021
04:54PM EST  GenMark Diagnostics Q4 EPS $(0.05) Misses $(0.01) Estimate, Sales $50.08M Beat $47.13M Estimate   Benzinga
08:08AM EST  The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants   Benzinga
04:03AM EST  Earnings Scheduled For February 25, 2021   Benzinga
Feb 22, 2021
04:10PM EST  GenMark Announced That Its ePlex Respiratory Pathogen Panel 2 Is Predicted To Detect Known Sars-Cov-2 Variants Currently In Circulation   Benzinga
04:05PM EST  GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that its ePlex Respiratory Pathogen Panel 2 (RP2) is predicted to detect known SARS-CoV-2 variants currently in circulation.   GlobeNewswire Inc
Feb 17, 2021
07:27AM EST  The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal   Benzinga
Feb 16, 2021
05:35PM EST  GenMark Diagnostics, Inc. (NASDAQ: GNMK) (GenMark or the Company), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41st Annual Health Care Conference.   GlobeNewswire Inc
04:04PM EST  GenMark Diagnostics Highlights Publication Of Manuscript In 'Frontiers in Cellular and Infection Microbiology' On ePlex Blood Culture ID Panels   Benzinga
04:03PM EST  Study Highlights Potential Clinical Value of ePlex   GlobeNewswire Inc
09:58AM EST  Canaccord Genuity Maintains Buy on GenMark Diagnostics, Raises Price Target to $24   Benzinga
Feb 11, 2021
04:17PM EST  GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close onThursday, February 25, 2021. Management will hold a conference call to review the company's financial performance starting at4:30 p.m. ETon the same day. The conference call will be concurrently webcast.   GlobeNewswire Inc
12:29PM EST  GenMark Surges On Report Of Potential Takeover Amid Interest From Buyers: Bloomberg   Benzinga
11:21AM EST  Stocks That Hit 52-Week Highs On Thursday   Benzinga
10:34AM EST  Shares of GenMark Diagnostics, Inc. (GNMK) are gaining over 27% on Thursday morning after a Bloomberg report said that the medical devices company is exploring a potential sale.   RTTNews
Jan 12, 2021
08:16AM EST  The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue   Benzinga
Jan 11, 2021
05:18PM EST  VOXX International Corp. (VOXX) - Shares of the electronics company surged 30% in extended trading session on Monday after the company reported strong third-quarter results. Third-quarter profit rose to $18.3 million or $0.74 per share from $2.2 million or $0.10 per share last year. Sales surged 82.6% to $201.1 million from $110.1 million last year.   RTTNews
04:55PM EST  Shares of GenMark Diagnostics Inc. (GNMK) gained over 7% on Monday after-hours after the molecular diagnostic testing systems maker issued a strong outlook for the fourth quarter and full year 2020.   RTTNews
04:10PM EST  GenMark Diagnostics Sees Q4 2020 Revs. ~$50M Vs Average Est. $45.87M   Benzinga
04:09PM EST  GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2020.   GlobeNewswire Inc
Dec 28, 2020
04:05PM EST  GenMark Diagnostics, Inc. (NASDAQ: GNMK) (GenMark or the Company), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences.   GlobeNewswire Inc
Oct 29, 2020
07:30AM EDT  The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal   Benzinga
Oct 28, 2020
04:22PM EDT  UPDATE: GenMark Raises FY20 Sales Guidance From $155M-$165M To $165M-$168M vs $164.2M Estimate   Benzinga
04:22PM EDT  GenMark Raises Guidance   Benzinga
04:21PM EDT  GenMark Diagnostics Q3 EPS $(0.05) Beats $(0.06) Estimate, Sales $42.65M Beat $39.26M Estimate   Benzinga
04:05PM EDT  GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended September30, 2020.   GlobeNewswire Inc
Oct 14, 2020
05:21PM EDT  GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its third quarter earnings results after market close onWednesday, October 28, 2020. Management will hold a conference call to review the company's financial performance starting at1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. The conference call will be concurrently webcast.   GlobeNewswire Inc
Oct 9, 2020
12:49PM EDT  GenMark Diagnostics shares are trading higher after the company announced it sees Q3 sales of $42.6 million, versus the $38.09 million estimate.   Benzinga
08:36AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Friday, Oct. 9, 2020: JPM, JNPR, VLDR, GNMK, GRFS   Benzinga
Oct 8, 2020
05:30PM EDT  GameStop Corp. (GME) - Shares of the retailer gained 12% in extended trading session Thursday on top of 44% surge in regular trading. The company announced that it has entered into a multi-year strategic partnership agreement with Microsoft Corp. (MSFT).   RTTNews
04:40PM EDT  GenMark Diagnostics Inc. (GNMK), Thursday said it has received Emergency Use Authorization from the U.S. Food and Drug Administration for its ePlex Respiratory Pathogen Panel 2.   RTTNews
04:07PM EDT  GenMark Diagnostics Announces That Its ePlex Respiratory Pathogen Panel 2 Received EUA From FDA   Benzinga
04:05PM EDT  GenMark Diagnostics ePlex   GlobeNewswire Inc
04:04PM EDT  GenMark Diagnostics Sees Q3 Sales $42.6M Vs. $38.09M Est.   Benzinga
04:03PM EDT  GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary financial results for the quarter ended September 30, 2020.   GlobeNewswire Inc
Sep 22, 2020
07:07AM EDT  Milestone Pharma Appoints Lisa Giles And Robert Wills To Board, Effective October 1   RTTNews
07:01AM EDT  Milestone Pharmaceuticals Appoints Lisa Giles And Robert Wills To Its Board   RTTNews
07:01AM EDT  Milestone Pharmaceuticals Strengthens Board of Directors with Two New   PR Newswire
Sep 14, 2020
04:06PM EDT  GenMark Diagnostics' ePlex Respiratory Pathogen Panel 2 Achieves CE Mark; Molecular Syndromic Test For COVID-19, Influenza, Other Common Respiratory Pathogens   Benzinga
04:05PM EDT  Molecular syndromic test for COVID-19, influenza and other common respiratory pathogenshelps health care professionals prepare for flu season   GlobeNewswire Inc
Aug 17, 2020
08:20AM EDT  GenMark Reports Submission Of Emergency Use Authorization For Its ESensor SARS-CoV-2 Test   RTTNews
08:01AM EDT  GenMark Diagnostics Announces Submission of Emergency Use Authorization for its eSensor SARS-CoV-2 Test   Benzinga
08:00AM EDT  GenMark Diagnostics Announces Submission of Emergency Use   GlobeNewswire Inc
Aug 6, 2020
07:57AM EDT  The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO   Benzinga
Aug 5, 2020
06:53AM EDT  Needham Maintains Buy on GenMark Diagnostics, Raises Price Target to $22   Benzinga
Aug 4, 2020
05:21PM EDT  Recap: GenMark Diagnostics Q2 Earnings   Benzinga
04:32PM EDT  GenMark Diagnostics Raises FY20 Sales From $120M-$130M To $155M-$165M   Benzinga
04:31PM EDT  GenMark Diagnostics Q2 EPS $(0.07) Beats $(0.09) Estimate, Sales $40.10M Beat $32.74M Estimate   Benzinga
05:19AM EDT  Earnings Scheduled For August 4, 2020   Benzinga
Jul 29, 2020
04:06PM EDT  GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences.   GlobeNewswire Inc
Jul 21, 2020
04:05PM EDT  GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its second quarter earnings results after market close onTuesday, August 4, 2020. Management will hold a conference call to review the company's financial performance starting at1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. The conference call will be concurrently webcast.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC